Stockscreener 앱 받기
9.80
1.66%
0.16
전일 마감가:
$9.64
열려 있는:
$9.5
하루 거래량:
3,073
Relative Volume:
0.32
시가총액:
$693.63M
수익:
$370.44M
순이익/손실:
$12.19M
주가수익비율:
56.88
EPS:
0.1723
순현금흐름:
$50.74M
1주 성능:
+2.83%
1개월 성능:
-7.11%
6개월 성능:
-44.94%
1년 성능:
-31.82%
1일 변동 폭
$9.50
$10.03
1주일 범위
$9.32
$9.90
52주 변동 폭
$9.32
$21.34
Pharming Group Nv Adr Stock (PHAR) Company Profile
Compare PHAR vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHAR
Pharming Group Nv Adr
|
9.80 | 693.63M | 370.44M | 12.19M | 50.74M | 0.1723 |
VRTX
Vertex Pharmaceuticals Inc
|
509.80 | 129.21B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.94 | 94.99B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.89 | 82.56B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.51 | 53.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.87 | 42.07B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pharming Group Nv Adr Stock (PHAR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Canaccord Genuity | Buy |
| 2024-12-09 | 개시 | Jefferies | Buy |
Pharming Group Nv Adr 주식(PHAR)의 최신 뉴스
Zai Lab LimitedADR Peer Comparison – Compare with Others - valueresearchonline.com
PHAR Q2 2026 Earnings: EPS Falls 90% Short of ConsensusAnalyst Drop Coverage - careplusvn.com
PHAR Q2 2026 Earnings: EPS Falls 90% Short of ConsensusEarnings Season Preview - dars.gov.et
PHAR Q2 2026 Earnings: EPS Falls 90% Short of ConsensusBalance Sheet Strength - dars.gov.et
Pharming Group (PHAR) Slips 3.22% to $11.11: Key Support Zone in FocusHagopian Line - careplusvn.com
Pharming Group (PHAR) Slips 3.22% to $11.11: Key Support Zone in FocusDescending Triangle - dars.gov.et
Pharming Group (PHAR) Slips 3.22% to $11.11: Key Support Zone in FocusOversold Bounce Ideas - dars.gov.et
XORTX Therapeutics Inc. (XRTX) Peer Comparison – Compare with Others - Value Research
Pharming (PHAR) Quarterly Results: The EPS Result Is Below Expectation in the Latest Session; Investor Response: Shares Move Lower 0.30% in the Current UpdateSlow Growth Warning - dars.gov.et
Pharming (PHAR) EPS and Revenue: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; After Earnings: The Market Price Declines 1.43% on the DayEarnings Preview - dars.gov.et
Pharming (PHAR) EPS and Revenue: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; After Earnings: The Market Price Declines 1.43% on the DayMargin Expansion Trends - dars.gov.et
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 93.0% in July - MarketBeat
Pharming Group (PHAR) Slides 5.1% to $11.72 as Rare-Disease Biotech Faces Selling PressureTrading Ideas - careplusvn.com
Pharming Group (PHAR) Slides 5.1% to $11.72 as Rare-Disease Biotech Faces Selling PressureInsider Selling Alerts - dars.gov.et
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Brokerages - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap DownShould You Sell? - MarketBeat
Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Pharming (PHAR) Q2 2026 Earnings: 90% EPS Miss Overshadowed by Resilient Share PriceRevenue Warning Signal - careplusvn.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pharming Grou - The National Law Review
Pharming Group (PHAR) Securities Investigation NoticeLevi & Korsinsky - Sahm
Pharming Group (NASDAQ:PHAR) Shares Gap UpTime to Buy? - MarketBeat
Pharming Group (PHAR) Advances 1.93% to $10.01, Approaches Key Resistance at $10.51IV Spike - careplusvn.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Q3 EPS Estimates for Pharming Group Lowered by HC Wainwright - MarketBeat
PHAR Q2 2026 Earnings: Marginal EPS Miss Triggers 15.5% SelloffCFO Commentary Report - careplusvn.com
Pharming Group (NASDAQ:PHAR) Shares Gap Down Following Weak Earnings - MarketBeat
PHAR Q2 2026 Earnings: Marginal EPS Miss Triggers 15.5% SelloffSurprise Factor Analysis - dars.gov.et
PHAR Q2 2026 Earnings: Marginal EPS Miss Triggers 15.5% SelloffEarnings Surprise Score - https://www.dars.gov.et/
Pharming Q2 2026 slides: Joenja growth offsets RUCONEST pressure - investing.com
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update - MarketBeat
Pharming Group NV Sponsored ADR Revenue Breakdown – DUS:PHG - TradingView
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Analysts - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap DownHere's What Happened - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Pharming Group N.V - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Pharming Group N.V - The National Law Review
A2QLQY Forecast — Price Target — Prediction for 2027 - TradingView
Pharming Group NV Sponsored ADR Actuals & Estimates (NASDAQ:PHAR) - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
A2QLQY Forecast — Price Target — Prediction for 2027 - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Form 6K Pharming Group NV For: 28 May By Investing.com - Investing.com South Africa
Pharming Group Nv Adr (PHAR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.52%
0.31%
자본화:
|
볼륨(24시간):